Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a buy rating to a strong-buy rating in a research note published on Thursday.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ:AUPH opened at $8.34 on Thursday. Aurinia Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $10.67. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -55.60 and a beta of 1.24. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock’s 50-day simple moving average is $8.73 and its two-hundred day simple moving average is $7.20.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $8.43, for a total value of $38,415.51. Following the completion of the sale, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. This represents a 25.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AUPH. State Street Corp raised its stake in Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after purchasing an additional 64,949 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Aurinia Pharmaceuticals by 13.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after buying an additional 89,940 shares during the last quarter. Segall Bryant & Hamill LLC boosted its position in shares of Aurinia Pharmaceuticals by 1.6% during the third quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock worth $4,125,000 after acquiring an additional 9,031 shares during the last quarter. SG Americas Securities LLC grew its stake in Aurinia Pharmaceuticals by 4,307.9% during the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock valued at $4,015,000 after acquiring an additional 535,301 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Aurinia Pharmaceuticals by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock valued at $2,791,000 after acquiring an additional 77,510 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.